Trial reportAntimicrobial agents and chemotherapy2017
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
Erratum issued 2 registry-linked trialsAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial of High-Dose Rifampin in Patients With New, Smear-Positive TB
A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2018Pooled it
- Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial.The Journal of infectious diseases · 2026Trial
- Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial.The Journal of infectious diseases · 2025Trial
- Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol.BMC infectious diseases · 2018Trial
- Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.American journal of respiratory and critical care medicine · 2018Trial
- Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018Trial
- Efficacy and safety of daily drug regimens containing high-dose versus standard-dose rifampicin for treating pulmonary tuberculosis: Systematic review and meta-analysis.Lung India : official organ of Indian Chest Society · 2026Article
- Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Clinical Pharmacokinetics of Antitubercular Drugs in the Overweight and Obese Population: Implications for Dosage Adjustments.Clinical pharmacokinetics · 2025Review
- Therapeutic drug monitoring in tuberculosis.European journal of clinical pharmacology · 2024Review
- Phenotypic drug susceptibility characterization and clinical outcomes of tuberculosis strains with A-probe mutation by GeneXpert MTB/RIF.BMC infectious diseases · 2023Article
- A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.Drug delivery and translational research · 2023Review
- Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients.Antimicrobial agents and chemotherapy · 2022Article
- Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study.The Lancet. Microbe · 2021Article
- Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.Antimicrobial agents and chemotherapy · 2021Article
- Tuberculosis in Hospitalized Patients With Human Immunodeficiency Virus: Clinical Characteristics, Mortality, and Implications From the Rapid Urine-based Screening for Tuberculosis to Reduce AIDS Related Mortality in Hospitalized Patients in Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Article
- In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis.PLoS neglected tropical diseases · 2020Article
- Both Pharmacokinetic Variability and Granuloma Heterogeneity Impact the Ability of the First-Line Antibiotics to Sterilize Tuberculosis Granulomas.Frontiers in pharmacology · 2020Article
- Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.Clinical pharmacokinetics · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
C A PeloquinUniversity of Florida College of Pharmacy and Emerging Pathogens Institute, Gainesville, Florida, USA peloquin@cop.ufl.edu.
G E VelásquezDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-1438-0692
L LeccaDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
R I CalderónSocios En Salud, Lima, Peru.
J CoitDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
M MilsteinDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
E OssoDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
J JimenezSocios En Salud, Lima, Peru.
K TintayaSocios En Salud, Lima, Peru.
E Sanchez GaravitoHospital Nacional Sergio Bernales, Lima, Peru.
D Vargas VasquezHospital Nacional Hipólito Unanue, Lima, Peru.
C D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
G DaviesInstitutes of Infection and Global Health and Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
Funding
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TBU01AI091429 · NIAID · HARVARD MEDICAL SCHOOL · PI DAVIES, GERAINT, MITNICK, CAROLE D. · 2011 to 2013
$8.5MNIAID NIH HHS L30 AI120170NIAID NIH HHS U01 AI091429
Abstract
Rifamycins exhibit concentration-dependent killing of
Indexed as
Administration, OralAdolescentAdultAntitubercular AgentsDose-Response Relationship, DrugFemaleHumansMaleMycobacterium tuberculosisPeruRifampinTuberculosisYoung AdultAntitubercular AgentsRifampinantitubercular agentspharmacokineticsrifampintuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01408914ClinicalTrials.gov
NCT03982277ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.